Leerink Partnrs Has Positive Outlook of ASND FY2024 Earnings

Ascendis Pharma A/S (NASDAQ:ASND) – Leerink Partnrs lifted their FY2024 earnings per share estimates for shares of Ascendis Pharma A/S in a research report issued to clients and investors on Monday, January 20th. Leerink Partnrs analyst J. Schwartz now forecasts that the biotechnology company will post earnings of ($6.44) per share for the year, up from their prior estimate of ($6.50). The consensus estimate for Ascendis Pharma A/S’s current full-year earnings is ($7.11) per share. Leerink Partnrs also issued estimates for Ascendis Pharma A/S’s Q4 2024 earnings at ($0.26) EPS, Q1 2025 earnings at ($1.90) EPS, Q2 2025 earnings at ($1.81) EPS, Q3 2025 earnings at ($1.74) EPS, Q4 2025 earnings at ($1.66) EPS, FY2025 earnings at ($7.12) EPS and FY2026 earnings at ($2.00) EPS.

A number of other research analysts also recently weighed in on ASND. Oppenheimer lowered their price target on Ascendis Pharma A/S from $190.00 to $180.00 and set an “outperform” rating on the stock in a report on Friday, November 15th. Wedbush reaffirmed an “outperform” rating and issued a $181.00 price target on shares of Ascendis Pharma A/S in a research report on Friday, November 15th. TD Cowen reduced their price target on Ascendis Pharma A/S from $160.00 to $153.00 and set a “buy” rating for the company in a research report on Friday, November 15th. UBS Group initiated coverage on Ascendis Pharma A/S in a research report on Tuesday, January 7th. They issued a “buy” rating and a $196.00 price target for the company. Finally, StockNews.com raised Ascendis Pharma A/S from a “sell” rating to a “hold” rating in a research report on Wednesday, November 20th. Two analysts have rated the stock with a hold rating and thirteen have assigned a buy rating to the stock. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $192.07.

Ascendis Pharma A/S Stock Up 1.3 %

Shares of Ascendis Pharma A/S stock opened at $127.49 on Wednesday. The stock’s fifty day moving average is $133.25 and its 200-day moving average is $133.30. The firm has a market capitalization of $7.74 billion, a PE ratio of -15.78 and a beta of 0.65. Ascendis Pharma A/S has a 12-month low of $111.09 and a 12-month high of $161.00.

Hedge Funds Weigh In On Ascendis Pharma A/S

Several large investors have recently added to or reduced their stakes in the company. Signaturefd LLC raised its holdings in Ascendis Pharma A/S by 13.2% in the 3rd quarter. Signaturefd LLC now owns 686 shares of the biotechnology company’s stock valued at $102,000 after acquiring an additional 80 shares in the last quarter. Profund Advisors LLC raised its holdings in Ascendis Pharma A/S by 3.0% in the 2nd quarter. Profund Advisors LLC now owns 2,919 shares of the biotechnology company’s stock valued at $398,000 after acquiring an additional 85 shares in the last quarter. Rhumbline Advisers grew its stake in shares of Ascendis Pharma A/S by 10.3% in the 2nd quarter. Rhumbline Advisers now owns 1,533 shares of the biotechnology company’s stock valued at $209,000 after purchasing an additional 143 shares during the period. Wilmington Savings Fund Society FSB bought a new stake in shares of Ascendis Pharma A/S in the 3rd quarter valued at approximately $30,000. Finally, GAMMA Investing LLC grew its stake in shares of Ascendis Pharma A/S by 58.0% in the 4th quarter. GAMMA Investing LLC now owns 583 shares of the biotechnology company’s stock valued at $80,000 after purchasing an additional 214 shares during the period.

Ascendis Pharma A/S Company Profile

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates.